Details of Disease

General Information of Disease (ID: DIS5E5L7)

Disease Name	Hepatitis C
Synonyms	hepatic peliosis
Disease Class	1E50-1E51: Hepatitis virus infection
Definition	A vascular disease of the liver characterized by the occurrence of multiple blood-filled cysts or cavities. The cysts are lined with endothelial cells; the cavities lined with hepatic parenchymal cells (hepatocytes). Peliosis hepatis has been associated with use of anabolic steroids (anabolic agents) and certain drugs.
Disease Hierarchy	DISW8GMJ: Hepatic vascular disorder DIS5E5L7: Hepatitis C
ICD Code	ICD-11 ICD-11: 1E51 ICD-10 ICD-10: B18.2 Expand ICD-10 C91,B17,B18 Expand ICD-9 202.4,070.4,070.5,070.70
Disease Identifiers	MONDO ID MONDO_0004717 MESH ID D010382 UMLS CUI C0030781 MedGen ID 10618 SNOMED CT ID 58008004

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 4 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Interferon alfacon-1	DM90WJH	Approved	NA	[1]
Sofosbuvir	DMQI86A	Approved	Small molecular drug	[2]
Grazoprevir	DM9BPLW	Phase 4	NA	[2]
Ombitasvir	DMQIMTK	Phase 4	Small molecular drug	[2]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 4 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Ravidasvir	DM1LFUN	Phase 2/3	Small molecular drug	[3]
Paritaprevir	DM4N7BT	Phase 2	Small molecular drug	[2]
AT-777	DM7O89Q	Phase 1/2	Small molecular drug	[4]
AT-787	DMHYO38	Phase 1	Small molecular drug	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 1 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
F2RL3	TTD0652	Strong	Biomarker	[6]
------------------------------------------------------------------------------------

References

1	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	ClinicalTrials.gov (NCT03362814) Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.. U.S. National Institutes of Health.
4	ClinicalTrials.gov (NCT04309734) Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects. U.S. National Institutes of Health.
5	Clinical pipeline report, company report or official report of Atea Pharmaceuticals.
6	Role of fibrinogen and protease-activated receptors in acute xenobiotic-induced cholestatic liver injury.Toxicol Sci. 2011 Jan;119(1):233-43. doi: 10.1093/toxsci/kfq327. Epub 2010 Oct 25.